Lessons from the withdrawal of rofecoxib: Patients would be safer if drug companies disclosed adverse events before licensing

Patients would be safer if drug companies disclosed adverse events before licensing

Gardado en:
Detalles Bibliográficos
Main Authors: Dieppe, Paul A, Ebrahim, Shah, Martin, Richard M, Jüni, Peter
Formato: Artigo
Idioma:Inglês
Publicado: BMJ Group 2004
Assuntos:
Editorials
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC523096/
https://ncbi.nlm.nih.gov/pubmed/15485938
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares